| |
Success in today's competitive landscape hinges on awareness and informed decision making among patients, payers, and healthcare providers. Read the article for best practices in field force reporting and learn about the power of precision. 
|
|
| By Annalee Armstrong This year's Fierce 15 features companies pushing the envelope in the lab, clinic and boardroom. |
|
|
|
By Angus Liu On June 14, Merck & Co. posted a new entry on ClinicalTrials.gov. The study marked the 10th global phase 3 trial that the New Jersey pharma has logged for its Kelun Biotech-partnered ADC, sacituzumab tirumotecan, in about eight months. And Merck isn’t finished. |
By Angus Liu Bristol Myers Squibb, while working its way through a major restructuring, has unveiled another round of layoffs in its home state of New Jersey. |
By James Waldron The “strategic restructuring” is designed to push more resources into Vir’s hepatitis programs “and focus on the highest near-term value opportunities,” the biotech explained. |
|
Transform the Industry with Your Innovation! Submissions are now open for the Fierce Life Sciences Innovation Awards. Click to submit your entry and learn more about the categories and criteria. 
|
|
By Annalee Armstrong Fierce Biotech Associate Editor Gabrielle Masson presented the 2024 class of Fierce 15 winners on the floor of the New York Stock Exchange on Wednesday. |
By Kevin Dunleavy Adaptimmune has won accelerated FDA approval for Tecelra (afami-cel), a treatment for metastatic or unresectable synovial sarcoma which becomes the first engineered cell therapy for a solid tumor and the first new treatment in the indication in more than a decade. |
By Kevin Dunleavy Bayer’s transformation under CEO Bill Anderson has picked up momentum. In reporting second-quarter earnings on Tuesday, the company revealed it has cut 3,200 jobs since the start of this year. That number includes the 1,500 staffers the company said it laid off in the first quarter. |
By Heather Landi Testmaker Cepheid plans to eliminate 626 staff positions at its Sunnyvale, California headquarters by September 27, according to a regulatory filing. |
By Nick Paul Taylor Novo Nordisk has axed its once-monthly dual GLP-1/GIP receptor agonist, ending development of a drug candidate that it singled out as an exciting part of its pipeline earlier this year. |
By Andrea Park Genentech and the American Diabetes Association have a vision of a world with more equitable access to eye health care for all people with diabetes. |
By Heather Landi Neuralink has implanted its device in a second patient, according to the startup's owner Elon Musk. |
By Nick Paul Taylor Incyte is asking viewers to imagine a drug ad that provokes more excitement than eye rolls. Attaching a self-deprecating opening to an Opzelura TV spot, the biotech serves up a typical pharma ad while having a little fun with the responses such commercials can provoke. |
By Nick Paul Taylor Vertex’s attempt to treat a rare genetic disease has hit another setback. The biotech tossed two more drug candidates onto the discard pile in response to underwhelming data but, following a playbook that has worked in other settings, plans to use the missteps to inform the next wave of preclinical prospects. |
By Kevin Dunleavy Novo Nordisk’s attempt to gain an approval to treat heart failure patients with its obesity drug Wegovy has been put on hold. In its quarterly earnings presentation, the Danish company said that after discussions with the FDA, it has pulled its filing and expects to resubmit in early 2025. |
By James Waldron BioNTech may still claim that the bispecific antibody acasunlimab has an “encouraging” clinical profile, but the mRNA leader has opted to end its involvement and allow partner Genmab to go solo for phase 3 trials. |
Fierce podcasts Don’t miss an episode |
| This week on “The Top Line,” we dive into two studies in HIV research that were presented at the 25th International AIDS Conference in Germany. |
|
|---|
|
|
Whitepaper The pharmaceutical industry faces ongoing challenges as the average drug development cost has increased by 15%, to now exceed $2 billion among leading biopharma companies. Download this playbook to discover the future of BioPharma financial analysis. Sponsored by: Visible Alpha, now a part of S&P Global Market Intelligence |
Whitepaper This paper explores the costs of setting up a supply chain in Europe for a new biopharma therapy. It outlines key cost drivers & the various levers decision makers can use to affect those costs. Sponsored by: AIM |
Whitepaper Download the white paper to learn how this innovative solution can help optimize your mAb production processes. The findings demonstrate the system's robust capability to sustain strong cell growth and high productivity, facilitating a smooth transition from laboratory to production scale. Sponsored by: Thermo Fisher Scientific |
Whitepaper Self-amplifying RNAs (also known as self-replicating RNAs), or saRNAs, are increasing in popularity as a platform for vaccine development. Download to learn how to make a more streamlined and efficient manufacturing of self-amplifying RNAs. Sponsored by: TriLink |
Whitepaper The definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond. Sponsored by: AVANT BIO |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
